Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2662459 | 1.00 | GCK (0.53) | GCKHTTRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL3388057 | 0.83 | GCK (0.56) | GCKHTTALDH1A1NPC1ATM | |
| SCHEMBL2662383 | 0.83 | GCK (0.56) | GCKHTTALDH1A1NPC1ATM | |
| SCHEMBL2652234 | 0.79 | GCK (0.48) | GCKRORC | |
| SCHEMBL2652233 | 0.79 | GCK (0.48) | GCKRORC | |
| SCHEMBL2658452 | 0.77 | GCK (0.49) | GCKHTTRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL3389187 | 0.77 | GCK (0.54) | GCKHTTALDH1A1RORCKDM4E | |
| SCHEMBL3389184 | 0.77 | GCK (0.54) | GCKHTTALDH1A1RORCKDM4E | |
| SCHEMBL2658456 | 0.77 | GCK (0.49) | GCKHTTRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL2020269 | 0.77 | GCK (0.40) | GCKHTTRAB9AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168962-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2010-03-31 | — | — | EP | claimed |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | claimed |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | OSI PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | claimed |
| EP-2168962-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-7582632-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-7214681-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | GPR119, IAPP, SLC5A1 | GCK 60/4885HTT 2760/4885RAB9A 3333/4885 |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | IAPP, GPR119, SLC5A1 | GCK 70/4885HTT 2557/4885RAB9A 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.